RGT — Argent BioPharma Balance Sheet
0.000.00%
- AU$11.13m
- AU$4.43m
- AU$3.39m
Annual balance sheet for Argent BioPharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 2.35 | 1.87 | 5.43 | 1.89 | 0.24 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.23 | 0.522 | 2.35 | 1.94 | 0.531 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3.72 | 3.23 | 9.48 | 6.46 | 2.53 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.47 | 4.02 | 7.14 | 8.8 | 7.45 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 13 | 7.93 | 24.2 | 18.6 | 9.98 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.18 | 2.97 | 6.13 | 7.71 | 13.3 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.04 | 4.82 | 10.4 | 12.7 | 17.4 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11 | 3.11 | 13.8 | 5.84 | -7.4 |
Total Liabilities & Shareholders' Equity | 13 | 7.93 | 24.2 | 18.6 | 9.98 |
Total Common Shares Outstanding |